Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) emerged from Wuhan, China at the end of December and spread rapidly around the globe with a higher degree of lethality reported than the endemic coronaviruses. Angiotensin convertase enzyme 2 (ACE2) host cell receptors mediate viral entry by binding to spike S protein of SARS-CoV2. ACE2 binding in viral pathogenesis has opened newer avenues for COVID-19 treatment with ACE2 at the center stage. Recombinant human ACE2 (rhACE2) protein has already shown therapeutic potential for vast array of therapeutic indications. In SARS-CoV2, the competitive binding of viral S protein with circulating ACE2 causing virus neutralization and sparing host ACE2 receptors is being proposed as the potential therapeutic mechanism in COVID-19. Though rhACE2 has moved into clinical trials in SARS-CoV2 patients, there are still some research gaps including lack of sufficient data about the proven efficacy of rhACE2 from in vitro and in vivo studies.